Brought to you by 
Series D lands $15.5mm for Daktari
04 Mar 2015
Executive Summary
Daktari Diagnostics Inc. (infectious disease tests) raised $15.5mm in its Series D financing led by new backer Eastern Capital and returning investor Merck Global Health Innovation Fund, which were joined by other existing shareholders Norwich Ventures and Partners Innovation Fund. Ferghana Partners was the placement agent. The company recently completed validation studies of its Daktari CD4 HIV platform and expects to launch the product globally this year.
Deal Industry
- In Vitro Diagnostics
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series D lands $15.5mm for Daktari
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice